血必净联合胸腺肽治疗肾综合征出血热的疗效：系统评价与Meta分析方案
Therapeutic effect of Xuebijing combined with thymosin on hemorrhagic fever with renal syndrome: A protocol of systematic review and meta-analysis.
作者信息
Li Chun-Mei, Sun Qi
机构信息
Department of Infectious Diseases, First Affiliated Hospital of Jiamusi University, Jiamusi, 154002.
Department of Infectious Diseases, Weihai Central Hospital, Weihai, 264400, China.
出版信息
Medicine (Baltimore). 2020 May;99(20):e20262. doi: 10.1097/MD.0000000000020262.
BACKGROUND
The goal of this study is to assess the therapeutic effect of Xuebijing combined with thymosin (XBJ-T) for the treatment of patients with hemorrhagic fever with renal syndrome (HFRS).
METHODS
We will search the electronic databases of Cochrane Library, PUBMED, EMBASE, PsycINFO, Scopus, Opengrey, Cumulative Index to Nursing and Allied Health Literature, Web of Science, Google scholar, Allied and Complementary Medicine Database, and Chinese Biomedical Literature Database from inception to the present. No language and publication status will be employed in this study. Based on the predefined eligibility criteria, selection of study and data extraction will be performed by 2 researchers independently. Study quality will be assessed using Cochrane risk of bias tool. We will apply RevMan 5.3 software to pool and analyze the extracted data.
RESULTS
This study will assess the therapeutic effect of XBJ-T for the treatment of patients with HFRS.
CONCLUSION
The findings of this study may provide systematic evidence to judge whether XBJ-T is an effective and safety intervention for HFRS.
STUDY REGISTRATION NUMBER
INPLASY202040068.
背景
本研究的目的是评估血必净联合胸腺肽（XBJ-T）治疗肾综合征出血热（HFRS）患者的疗效。
方法
我们将检索Cochrane图书馆、PUBMED、EMBASE、PsycINFO、Scopus、Opengrey、护理及相关健康文献累积索引、科学引文索引、谷歌学术、补充与替代医学数据库以及中国生物医学文献数据库等电子数据库，检索时间从建库至目前。本研究不设语言和发表状态限制。根据预先设定的纳入标准，由2名研究人员独立进行研究筛选和数据提取。采用Cochrane偏倚风险工具评估研究质量。我们将应用RevMan 5.3软件对提取的数据进行汇总和分析。
结果
本研究将评估XBJ-T治疗HFRS患者的疗效。
结论
本研究结果可为判断XBJ-T是否为HFRS的有效且安全的干预措施提供系统证据。
研究注册号
INPLASY202040068。
Zotero 插件